Business Wire

Incepto, the French Digital Health Specialist, is Raising €27 million to Support Its European Development

Share

Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today. The financing round is led by LBO France's Venture - Digital Health team, with the participation of Wille Finance and the historical investors AXA Venture Partners, the Patient Autonome fund of Bpifrance and Karista. This financing marks a new stage for Incepto, which is launching its offer in four new countries in Europe (Germany, Spain, Italy and Portugal).

As part of Incepto’s development, four new subsidiaries are created in Germany, Spain, Italy and Portugal with the aim of anchoring its position as European leader in the sector and treat one million European patients per month by 2024.

From a French start-up to a European scale-up

Incepto is also announcing the signing of five new partnerships (IB Lab, Milvue, PAIRE, SmartSoft and Thirona) to expand its portfolio of medical imaging applications for emergency care, oncology, orthopaedics, rheumatology and pneumology.

By extending its geographical coverage and developing its portfolio of applications, Incepto is responding to major public health issues: reducing waiting times for examinations, mitigating the lack of specialists for certain serious diseases and supporting doctors' work in the face of the increasing amount of data to be analysed.

In light with the explosion of the AI market in Europe, Incepto has three strategic objectives:

Selecting and make available the most powerful AI solutions in medical imaging for each specialty, guaranteeing high quality standards;

Creating, with doctors new applications that meet real needs but that do not exist yet: ARVA and KEROS are thus the first products co-developed by Incepto for the diagnostic assistance of aortic aneurysms in CT scanners and for MRI of the knee;

Supporting the transformation of organisations and working methods by rethinking patient care with medical teams to exploit the full potential of artificial intelligence technologies.

About Incepto

Created in 2018, Incepto is the first European platform for artificial intelligence solutions applied to medical imaging. With a hundred clinics equipped with their AI solutions and already more than 100,000 patients monitored every month, Incepto's mission is twofold: to help doctors identify the most efficient solutions and put them at their service, while co-creating new applications with them, adapted to their specific needs. Incepto's ambition is to assist doctors on a daily basis in improving the accuracy of diagnoses, the treatment process and the quality of patient care.

https://incepto-medical.com/fr

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contact
Aude Vayre : 00 33 6 14 64 15 65 / aude.vayre@grayling.com
Anne Levasseur : 00 33 6 68 52 14 09 / anne.levasseur@citigatedewerogerson.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acathia Capital Completes Acquisition of Swedish Life Insurer Futur Pension7.10.2022 12:51:00 EEST | Press release

With the receipt of approvals from the Swedish Financial Supervisory Authority, Acathia Capital has completed the increase of its stake in Futur Pension Försäkrings AB, the most successful life insurer in Sweden. Since 2019, Acathia Capital has been the joint lead investor, together with the Nordic private equity manager Polaris, in this investment, within a group of 5 institutional investors. As a result of the transaction, investment vehicles advised by Acathia have increased their joint stake in Futur Pension from 30% to almost 50%. Futur Pension is a powerful demonstration of how digitalization is fundamentally transforming the insurance business. The fintech, founded in 2000, has already fundamentally transformed the Swedish life insurance market in terms of cost and market share structure. Dr. Thomas Schmitt, managing partner of Acathia Capital, comments: “Futur Pension has increased its market share from 7% to over 11% of premium volume since we have become owners in 2019, makin

EIG’s MidOcean Energy to Acquire Tokyo Gas’ Interests in Portfolio of Four Australian Integrated LNG Projects for US$2.15 Billion7.10.2022 11:44:00 EEST | Press release

MidOcean Energy (“MidOcean”), an LNG company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced that it has entered into a definitive agreement with Tokyo Gas Co., Ltd (“Tokyo Gas”) to acquire Tokyo Gas’ interests in a portfolio of four Australian integrated LNG projects. Under the terms of the agreement, MidOcean will acquire Tokyo Gas’ interests in Gorgon LNG, Ichthys LNG, Pluto LNG and Queensland Curtis LNG for total cash consideration of US$2.15 billion. These integrated projects span Australia’s western and eastern seaboard and are major suppliers of LNG to Asia, with a diverse set of long-dated take or pay contracts with investment grade counterparties, and to Australia’s domestic gas markets. The portfolio is expected to generate approximately 1 million tonnes per annum of LNG net to MidOcean, production that is underpinned by long-life reserves and a globally competitive cost structure. The portfolio bene

Slate Asset Management Provides Fleet Financing to Move About Group AB to Support Rollout of Electric Vehicles and Charging Infrastructure Across Europe7.10.2022 10:00:00 EEST | Press release

Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that it has agreed to provide financing to Move About Group AB (“Move About”), a Swedish electric mobility service, to support the roll out of more than 150 electric vehicles and electric vehicle charging infrastructure throughout Europe. The car funding provided by Slate will be used to bolster Move About’s electric car fleet, which currently owns and operates over 800 electric cars and has more than 71,000 users on its platform. Move About is a Sweden-based electric mobility service that delivers environmentally friendly and cost-effective mobility solutions to over 300 locations across Sweden, Norway, and Germany. Move About has partnered with some of the largest companies across Europe to save tons of carbon dioxide emissions every year. Since it was founded in 2007, Move About has become the largest provider of emission-free carsharing in the Nordic region. Christian S

LabGenius Secures Government Innovation Grant to Expand ML-driven Drug Discovery Platform, EVA™7.10.2022 10:00:00 EEST | Press release

LabGenius, a pioneer in the use of machine learning (ML) for antibody engineering, today announced that it has been awarded a highly competitive SMART grant from Innovate UK. Grants from the £25 million fund allow businesses like LabGenius to realize the potential of new ideas by investing in game-changing, commercially viable research and development projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221007005023/en/ To date, LabGenius’ EVA platform has been used to co-optimize mono- and multi-specific single domain antibodies for biochemical and bio functional properties, including stability, potency and selective tumor cell killing. This grant will be used to further expand EVA 's capabilities by accelerating the platform’s ability to optimize antibody-based immune cell engager molecules. Many existing antibody therapeutics have poor selective cell killing profiles, which can result in on-target, off-tumor effects,

Valbiotis Accelerates Its Marketing Strategy7.10.2022 08:35:00 EEST | Press release

Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy. Sébastien PELTIER, Chairman of the Valbiotis Board of Directors, states: "Today, we are embarking on a complementary development cycle to commercialize our innovative active substances, with the aim of providing breakthrough solutions for reducing the risk factors of cardio-metabolic diseases. Our new strategy aims to accelerate the growth of Valbiotis and to boost its capacity for innovation using two main levers: firstly, the signing of international partnerships (global or regional) with major players in the nutrition and healthcare sectors, supported by the specialist firm AEC Partners1, and secondly, the company's own marketing of its products on the French market. This dual strategy, creating value, will enable Valbiotis to rapidly tar

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom